Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.42 USD | 0.00% | +2.90% | +33.96% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 8M | Capitalization | 82.01M |
---|---|---|---|---|---|
Net income 2024 * | -38M | Net income 2025 * | -37M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 10.3 x |
P/E ratio 2024 * |
-2.03
x | P/E ratio 2025 * |
-2.05
x | Employees | 16 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.73% |
Latest transcript on SELLAS Life Sciences Group, Inc.
1 week | +2.90% | ||
Current month | +0.71% | ||
1 month | +10.08% | ||
3 months | +37.86% | ||
6 months | +30.28% | ||
Current year | +33.96% |
Managers | Title | Age | Since |
---|---|---|---|
Angelos Stergiou
FOU | Founder | 48 | 06-04-02 |
John Burns
DFI | Director of Finance/CFO | 39 | 13-04-30 |
Andrew Elnatan
LAW | General Counsel | - | 23-01-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 67 | 17-12-28 | |
David Scheinberg
BRD | Director/Board Member | 68 | 17-11-30 |
John Varian
BRD | Director/Board Member | 64 | 17-12-28 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-04 | 1.41 | -0.70% | 170 457 |
24-06-03 | 1.42 | +0.71% | 534,074 |
24-05-31 | 1.41 | +0.71% | 571,466 |
24-05-30 | 1.4 | +3.70% | 477,270 |
24-05-29 | 1.35 | -2.17% | 459,162 |
Delayed Quote Nasdaq, June 04, 2024 at 01:22 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.96% | 82.01M | |
+15.57% | 121B | |
+13.47% | 107B | |
-5.13% | 24.82B | |
+1.69% | 22.48B | |
-10.09% | 18.32B | |
-40.52% | 16.33B | |
-14.47% | 15.31B | |
+2.97% | 14.08B | |
+25.00% | 11.74B |
- Stock Market
- Equities
- SLS Stock